Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

Key Points

• Algert Global increased its Vir Biotechnology stake by 64.6% in the second quarter, purchasing 315,969 additional shares and bringing its holdings to 804,977 shares valued at approximately $8.2 million.
• Vir Biotechnology reported quarterly EPS of $0.47, beating estimates of $0.33, while revenue reached $238.95 million versus the $135.88 million consensus estimate. However, the company continues to post substantial losses, including a negative net margin of 638.88%.
• Analyst sentiment is generally positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $21.57, compared with shares trading at $11.08.

Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 64.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804,977 shares of the company's stock after buying an additional 315,969 shares during the period. Algert Global LLC owned 0.48% of Vir Biotechnology worth $8,203,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Vir Biotechnology in the 2nd quarter worth $35,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock valued at $41,000 after acquiring an additional 1,390 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock worth $43,000 after acquiring an additional 6,597 shares during the period. CWM LLC grew its holdings in shares of Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company's stock worth $53,000 after acquiring an additional 1,646 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Vir Biotechnology during the 4th quarter valued at $60,000. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Stock Performance

Shares of NASDAQ VIR opened at $11.08 on Thursday. The firm's fifty day moving average is $9.52 and its two-hundred day moving average is $9.26. Vir Biotechnology, Inc. has a 52-week low of $4.75 and a 52-week high of $11.66. The company has a market cap of $1.87 billion, a P/E ratio of -5.96 and a beta of 1.66.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The firm had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company's quarterly revenue was up 19582.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.80) EPS. As a group, analysts forecast that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VIR has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating on shares of Vir Biotechnology in a report on Monday, August 10th. Leerink Partners upped their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Wall Street Zen raised Vir Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $21.57.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the sale, the director owned 21,216 shares of the company's stock, valued at $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by company insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source